TMPO and breast carcinoma: Finally, preliminary studies have shown that TMPO-AS1 silencing can enhance sensitivity to paclitaxel (Dong et al., 2022) and docetaxel (Ning et al., 2021) in endometrial and breast cancers, respectively.